CD274 and breast cancer: Despite other targeted therapies, including PARP and programmed cell death-ligand 1 (PD-L1) targeting strategies, have been approved by FDA to treat BRCA-mutated or PD-L1-positive BC patients [74], the patients who can benefit from these therapies are still very limited.